Meplazumab

美珀珠单抗

Report date: 2024/06/12 15:33:20

Base Information

Drug NameMeplazumab
Drug Alias NameKetantinAnti-CD147 humanized meplazumabhumanized mAb against CD147HI6H8
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD147
TargetsBasigin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeMalaria, Falciparum +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBrazilMainland ChinaKenya
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.Institute Of Medicine Fourth Military Medical University
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeMalaria
Inactive IndicationsMalaria, Falciparum

Other Information

ATC CodeN/A
Related LinksN/A